Sodium-Glucose Cotransporter 2 Inhibitors Preceding ST-Segment Elevation Myocardial Infarction: Global Proteomics and Pathobiological Insights.

ABSTRACT:

Background

While sodium-glucose cotransport 2 receptor inhibitors (SGLT2i) improve post infarction cardiovascular outcomes, limited understanding exists on how these agents influence pathophysiology preceding myocardial infarction.

Objectives

The objective of this study was to explore how proteins are differentially regulated in patients on and not on an SGLT2i preceding ST-segment elevation myocardial infarction (STEMI).

Methods

Between June 2021 and October 2023, blood was collected at the time of arterial sheath insertion from consecutive STEMI patients. We then identified patients with diabetes and created propensity-matched pairs of patients on and not on SGLT2i prior to STEMI (SGLT2i+ and SGLT2i-). Serum was separated, and following immunodepletion and enzymatic

SUBMITTER: Shavadia JS 

PROVIDER: S-EPMC12219343 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature